What documentation is required when CIIs are sold to prescribers?

When selling Schedule II controlled substances to prescribers, it is essential to utilize a DEA 222 form initiated by the purchasing practitioner. This form acts as the official documentation required by the Drug Enforcement Administration (DEA) that provides a legal framework for the transfer of CII substances. The DEA 222 form serves several purposes: it ensures that both parties in the transaction are compliant with federal regulations, it maintains accountability for the controlled substances, and it allows tracking of the distribution and use of these highly regulated drugs.

Using the DEA 222 form is a critical step because it helps to prevent misuse and diversion of controlled substances. The form must be filled out properly, signed by the practitioner, and can be used to order or transfer CIIs. In the case of an order, it must be retained by the supplier and can be audited by the DEA if necessary. This level of documentation is not only essential for compliance but also protects both the supplier and the prescriber by maintaining an organized record of transactions involving potentially dangerous substances.

Alternative choices do not satisfy the legal obligations for controlled substance transactions. A verbal agreement lacks the necessary written documentation required for accountability, while a non-legal invoice does not carry the weight of regulatory compliance. The absence of any documentation would